Liersch T, Vehmeyer K, Kaboth U
Abteilung Hämatologie und Onkologie, Zentrum Innere Medizin, Universitätsklinikum Göttingen.
Med Klin (Munich). 1995 Jul 15;90(7):390-7.
Isovolemic large volume erythrocyte-apheresis (EA) is a rapid, effective and well-tolerated treatment modality for red blood cell (RBC) depletion in patients with polycythaemia vera (PV). According to clinical observations its long lasting effect (median interval from EA to EA about 6 months) may, at least in part, be due to the associated loss of iron.
Therefore we investigated the influence of EA on the proliferative capacity of erythroid (BFU-E) and granulocyte-macrophage (GM-CFU) progenitor cells and on the erythropoietin-(EPO-)independent, spontaneous in vitro growth of BFU-E in particular. In six patients RBC and iron parameters as well as the proliferative capacity of hematopoietic progenitor cells were determined before and after EA.
RBC parameters (in median) were before/after EA: RBC 7.64/5.93 x 10(6)/microliter; Hct 53/40%; Hb 15.5/12.0 g/dl and remained at reduced levels for several months; serum iron and ferritin levels decreased, while transferrin levels and transferrin receptor expression on peripheral mononuclear cells were enhanced. Serum EPO-levels were temporarily but only slightly increased. In all patients there was a significant inhibition of the growth of BFU-E detectable after EA while the GM-CFU were less affected. Within 3 to 6 weeks, the inhibition of endogenous BFU-E ranged from 53% to 100% and of EPO-dependent BFU-E from 31% to 74%. The inhibition of EA associated BFU-E growth could be reduced by in vitro addition of FeCl3. On the other hand, in vitro exposure of progenitor cells to an equivalent concentration of the iron chelator DFO (deferoxamine mesylate) resulted in a total suppression of progenitor cell growth.
Our data suggest that the long lasting effect of EA is not only due to the high volume removal of RBC itself, but also to the growth inhibition of EPO-independent and -dependent BFU-E which is obviously mediated by the considerable loss of iron by EA.
等容大容量红细胞单采术(EA)是一种快速、有效且耐受性良好的治疗真性红细胞增多症(PV)患者红细胞(RBC)增多的方法。根据临床观察,其持久效果(两次EA之间的中位间隔约为6个月)可能至少部分归因于伴随的铁流失。
因此,我们研究了EA对红系祖细胞(BFU-E)和粒-巨噬系祖细胞(GM-CFU)增殖能力的影响,尤其关注对BFU-E在促红细胞生成素(EPO)非依赖性、自发体外生长方面的影响。对6例患者在EA前后测定了RBC和铁参数以及造血祖细胞的增殖能力。
RBC参数(中位数)在EA前后分别为:RBC 7.64/5.93×10⁶/微升;血细胞比容53/40%;血红蛋白15.5/12.0克/分升,并在数月内维持在较低水平;血清铁和铁蛋白水平降低,而转铁蛋白水平及外周单个核细胞上转铁蛋白受体表达增强。血清EPO水平有短暂但仅轻微升高。所有患者在EA后均可检测到BFU-E生长受到显著抑制,而GM-CFU受影响较小。在3至6周内,内源性BFU-E的抑制率为53%至100%,EPO依赖性BFU-E的抑制率为31%至74%。体外添加FeCl₃可减轻EA相关的BFU-E生长抑制。另一方面,祖细胞在体外暴露于同等浓度的铁螯合剂去铁胺(DFO,甲磺酸去铁胺)会导致祖细胞生长完全受抑制。
我们的数据表明,EA的持久效果不仅归因于大量RBC的去除本身,还归因于对EPO非依赖性和依赖性BFU-E的生长抑制,这显然是由EA导致的大量铁流失介导的。